PI3K/Akt Pathway Activation Attenuates the Cytotoxic Effect of Methyl Jasmonate Toward Sarcoma Cells

被引:31
作者
Elia, Uri [1 ]
Flescher, Eliezer [1 ]
机构
[1] Tel Aviv Univ, Sackler Fac Med, Dept Human Microbiol, IL-69978 Tel Aviv, Israel
来源
NEOPLASIA | 2008年 / 10卷 / 11期
关键词
D O I
10.1593/neo.08636
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Methyl jasmonate (MJ) acts both in vitro and in vivo against various cancer cell lines. Activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway results in decreased susceptibility to cytotoxic agents in many types of cancer cells. We found a strong inverse correlation between the basal level of phospho-Akt (pAkt) and the sensitivity to MJ among sarcoma cell lines. Nevertheless, levels of pAkt increased in two sarcoma cell lines, MCA-105 and SaOS-2, after MJ treatment. Treatment of both cell lines with PI3K/Akt pathway inhibitors in combination with MJ resulted in a synergistic cytotoxic effect. Moreover, cells transfected with a constitutively active Akt were less susceptible to MJ-induced cytotoxicity in comparison with cells transfected with an inactive form of Akt. Taken together, these data suggest that the increase in pAkt after treatment with MJ played a protective role. Because it has been shown that the antiapoptotic effects of Akt are dependent on glycolysis, we examined the role of glucose metabolism in activation of Akt and the subsequent resistance of the cell lines to MJ. 2-Deoxy-D-glucose, a glycolysis inhibitor, decreased the levels of pAkt and was able to attenuate the MJ-induced elevation in pAkt. Accordingly, the presence of glucose attenuated MJ-induced cytotoxicity. Moreover, treatment with 2-deoxy-D-glucose in combination with MJ resulted in a synergistic cytotoxic effect. In conclusion, the PI3K/Akt pathway plays a critical role in the resistance of MCA-105 and SaOS-2 sarcoma cell lines toward MJ-induced cytotoxicity.
引用
收藏
页码:1303 / 1313
页数:11
相关论文
共 65 条
[31]   New emerging drugs in soft tissue sarcoma [J].
Milano, Amalia ;
Apice, Gaetano ;
Ferrari, Ettore ;
Fazioli, Flavio ;
de Rosa, Vincenzo ;
de Luna, Antonella Salzano ;
Iaffaioli, Rosario Vincenzo ;
Caponigro, Francesco .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2006, 59 (01) :74-84
[32]   Mitochondrial-targeted active Akt protects SH-SY5Y neuroblastoma cells from staurosporine-induced apoptotic cell death [J].
Mookherjee, Paramita ;
Quintanilla, Rodrigo ;
Roh, Myoung-Sun ;
Zmijewska, Anna A. ;
Jope, Richard S. ;
Johnson, Gail V. W. .
JOURNAL OF CELLULAR BIOCHEMISTRY, 2007, 102 (01) :196-210
[33]   Expression of phosphorylated Akt (pAkt) in gastric carcinoma predicts prognosis and efficacy of chemotherapy [J].
Murakami, Daiki ;
Tsujitani, Shunichi ;
Osaki, Tomohiro ;
Saito, Hiroaki ;
Katano, Kuniyuki ;
Tatebe, Shigeru ;
Ikeguchi, Masahide .
GASTRIC CANCER, 2007, 10 (01) :45-51
[34]  
Nakashio A, 2000, CANCER RES, V60, P5303
[35]   Elevated Akt activity protects the prostate cancer cell line LNCaP from TRAIL-induced apoptosis [J].
Nesterov, A ;
Lu, XJ ;
Johnson, M ;
Miller, GJ ;
Ivashchenko, Y ;
Kraft, AS .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2001, 276 (14) :10767-10774
[36]   PI3K-Akt pathway: Its functions and alterations in human cancer [J].
Osaki, M ;
Oshimura, M ;
Ito, H .
APOPTOSIS, 2004, 9 (06) :667-676
[37]   Activation of glycogen synthase kinase 30 disrupts the binding of hexokinase II to mitochondria by phosphorylating voltage-dependent anion channel and potentiates chemotherapy-induced cytotoxicity [J].
Pastorino, JG ;
Hoek, JB ;
Shulga, N .
CANCER RESEARCH, 2005, 65 (22) :10545-10554
[38]   Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention [J].
Pedersen, PL ;
Mathupala, S ;
Rempel, A ;
Geschwind, JF ;
Ko, YH .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOENERGETICS, 2002, 1555 (1-3) :14-20
[39]   Role of the phosphatidylinositol 3-kinase/Akt and mTOR/P70S6-kinase pathways in the proliferation and apoptosis in multiple myeloma [J].
Pene, F ;
Claessens, YE ;
Muller, O ;
Viguié, F ;
Mayeux, P ;
Dreyfus, F ;
Lacombe, C ;
Bouscary, D .
ONCOGENE, 2002, 21 (43) :6587-6597
[40]   Dwarfism, impaired skin development, skeletal muscle atrophy, delayed bone developement, and impeded adipogenesis in mice lacking Akt1 and Akt2 [J].
Peng, XD ;
Xu, PZ ;
Chen, ML ;
Hahn-Windgassen, A ;
Skeen, J ;
Jacobs, J ;
Sundararajan, D ;
Chen, WS ;
Crawford, SE ;
Coleman, KG ;
Hay, N .
GENES & DEVELOPMENT, 2003, 17 (11) :1352-1365